Logo Image
News
NewsPharma Pulse
Academy
Publications
Partner Perspectives
More
Webcasts
Resources
Conferences
Conference CoverageConference Listing
Events
Event Calendar
Videos
VideosPeer ExchangeShorts
Podcasts
Editorial PodcastsSponsored Podcasts

Subscribe

  • News
  • Academy
  • Publications
  • Partner Perspectives
  • Webcasts
  • Resources
  • Conferences
  • Events
  • Event Calendar
  • Videos
  • Podcasts
  • Subscribe
  • Brand & Product Security
    • Legal & Regulatory
    • Trade & Brand Protection
    • Traceability
  • Business and Finance
  • Cold Chain
    • Containers & Shippers
    • Software
    • Devices
  • Commercial Channels
  • Data & Technology
    • Real World Data
    • Digitalization
    • Artificial Intelligence
  • Logistics & Transportation
    • Manufacturing & Packaging
    • 3PL
    • Supply Chain
  • Market Access
    • Pricing
    • Commercialization
    • Trade & Channel
  • Opinion
  • Patient Support
    • Patient Assistance Programs
    • Hub Services
    • Adherence
Spotlight -
Latest Conference Coverage|
Digital Editions|
Supply Chain
Advertisement

John Tamisiea, McDermott, Will & Emery

Advertisement

Articles by John Tamisiea, McDermott, Will & Emery

Monetizing Intellectual Property: Royalties, Revenues and Alternative Sources of Capital

ByJeffrey Jung,John Tamisiea, McDermott, Will & Emery
April 10th 2010

Investment funds have developed an interest in trading capital for royalties on drug commercializations

Advertisement

Latest Updated Articles

  • Monetizing Intellectual Property: Royalties, Revenues and Alternative Sources of Capital
    Monetizing Intellectual Property: Royalties, Revenues and Alternative Sources of Capital

    April 10th 2010



Advertisement
Advertisement

Trending on Pharmaceutical Commerce

1

Cardinal Health, McKesson Extend CVS Distribution Deals to 2032

2

Doceree CEO: AI Should Extend the Field Force, Not Replace It

3

What to Watch at LogiPharma: Resilience, Practical AI and New Peer Formats

4

How the GLP-1 Boom Stress-Tests the Pharma Cold Chain

5

Why Waltz Health, Fresenius Kabi Are Taking Biosimilars Direct

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us